Gilead partners with 5 generic drugmakers on remdesivir supply expansion

May 12, 2020

Gilead Sciences has signed non-exclusive licensing pacts with Jubilant Life Sciences, Cipla, Hetero Labs, Mylan and Ferozsons Laboratories. The five generics drugmakers will help expand the supply of Gilead's experimental COVID-19 treatment remdesivir by making and selling the drug in 127 countries.

The five generic drugmakers are based in India and Pakistan. According to Gilead, the licensees will set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding COVID-19, or until a product other than remdesivir or a vaccine is approved to treat or prevent COVID-19.

Gilead’s antiviral drug remdesivir earlier this month received the U.S. Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.

Read the Reuters report